source
- FDA’s AI push faces uncertainty after key leaders departThe FDA has been pushing artificial intelligence across the agency, unveiling a large-language-model tool called Elsa to help draft and summarize review reports and announcing plans to use agentic…
- Oak Hill Bio to go public via SPAC merger, securing $175 million for Angelman syndrome programOak Hill Bio announced it will become a publicly traded company through a merger with the special purpose acquisition company Research Alliance Corporation III. The transaction will provide $75 mi…